Evaluation of a Patient-Reported Symptom Index for NMIBC

CompletedOBSERVATIONAL
Enrollment

498

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 30, 2020

Study Completion Date

August 30, 2021

Conditions
Superficial Bladder Cancer
Trial Locations (19)

2065

Royal North Shore Hospital, St Leonards

2139

Concord Hospital, Concord

2145

The Urological Cancer Centre, Westmead Specialist Centre, Westmead

Westmead Hospital, Westmead

2650

Riverina Cancer Care Centre, Wagga Wagga

3004

Alfred Health, Melbourne

3052

Royal Melbourne Hospital, Parkville

3084

Austin Health, Heidelberg

3128

Box Hill Hospital, Box Hill

3140

Tauranga Urology Research, Tauranga

3189

Monash Health, Moorabbin

4101

Mater Misericordiae Limited, South Brisbane

6150

Fiona Stanley Hospital, Murdoch

8013

Canterbury Urology Research Trust, Christchurch

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

66160

University of Kansas, Kansas City

Unknown

University of British Columbia, Vancouver

M5 5AP

Salford Royal NHS Foundation Trust, Salford

All Listed Sponsors
collaborator

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER

collaborator

Cancer Australia

OTHER

collaborator

Cancer Council New South Wales

OTHER

lead

University of Sydney

OTHER

NCT03091764 - Evaluation of a Patient-Reported Symptom Index for NMIBC | Biotech Hunter | Biotech Hunter